Authorised Phase I and Phase II (Integrated)- First administration to humans Newly diagnosed, stage III or IV amenable to surgery, HPV negative, squamous-cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx (SCCHN) for patients who have completed and a documented complete response to gross total resection of the primary tumor and standard adjuvant therapy.

A phase I/II trial of TG4050, an individualised gene therapy, in patients with advanced cancer of the head and neck.

EU CTIS ID: 2023-508561-33-00

What this study is testing

Phase I and Phase II (Integrated)- First administration to humans

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Where it's taking place

United States
United Kingdom

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include United States; United Kingdom. Enter your location above to see the nearest site and check your eligibility.

Find trials near you

This trial is registered in the EU. Search recruiting trials near you for Newly diagnosed, stage III or IV amenable to surgery, HPV negative, squamous-cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx (SCCHN) for patients who have completed and a documented complete response to gross total resection of the primary tumor and standard adjuvant therapy. - answer a few quick questions and apply in minutes.

Full record on EU CTIS

SponsorTransgene

Target enrollment98

Explore other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH)Heart failure Coronary artery disease

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.